United Therapeutics (NASDAQ:UTHR) CEO Sells $5,215,120.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $548.96, for a total transaction of $5,215,120.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,240,016.48. The trade was a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Trading Up 2.0%

UTHR stock traded up $10.74 during trading hours on Tuesday, hitting $557.99. 120,736 shares of the stock were exchanged, compared to its average volume of 494,100. The company has a 50-day simple moving average of $557.83 and a two-hundred day simple moving average of $528.36. The firm has a market capitalization of $23.69 billion, a P/E ratio of 20.60, a P/E/G ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.63 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arjuna Capital boosted its stake in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC lifted its holdings in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC lifted its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance grew its holdings in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on UTHR. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research report on Thursday, May 7th. Bank of America raised their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Finally, Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.